Scholar Rock Holding (SRRK) Consolidated Net Income (2017 - 2026)

Scholar Rock Holding's (SRRK) quarterly Consolidated Net Income came in at -$101.4 million in Q1 2026, down 35.42% year-on-year from -$157.1 million in Q1 2025, and down 13.37% quarter-over-quarter from -$89.5 million in Q4 2025.

Scholar Rock Holding (SRRK) Consolidated Net Income (2017 - 2026) Analysis & Trends

Scholar Rock Holding's Consolidated Net Income history runs 10 years deep, the most recent figure standing at -$101.4 million for Q1 2026.

  • On a quarterly basis, Consolidated Net Income fell 35.42% year-over-year to -$101.4 million in Q1 2026; TTM through Mar 2026 was -$715.2 million, a 166.34% decrease from a year earlier, with the FY2025 full-year figure at -$377.7 million, down 53.37% from the prior year.
  • Consolidated Net Income declined to -$101.4 million in Q1 2026 per SRRK's latest filing, from -$89.5 million in the prior quarter.
  • Across five years, Consolidated Net Income topped out at -$9.2 million in Q1 2022 and bottomed at -$263.8 million in Q2 2025.
  • The 5-year median for Consolidated Net Income is -$56.8 million (2024), against an average of -$80.2 million.
  • Across the five-year window, Consolidated Net Income soared 93.69% in 2022 and sank 383.1% in 2023, its largest moves.
  • Year by year, Consolidated Net Income stood at -$41.8 million in 2022, then fell by 18.96% to -$49.7 million in 2023, then plunged by 36.16% to -$67.7 million in 2024, then sank by 32.26% to -$89.5 million in 2025, then declined by 13.37% to -$101.4 million in 2026.
  • Per Business Quant, the three latest SRRK Consolidated Net Income figures stand at -$101.4 million (Q1 2026), -$89.5 million (Q4 2025), and -$260.5 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Consol Net Inc. (Qtr)
1 Oculis Holding AG 66,320.50 Bn 66,320.21 Bn - -37.09 Mn
2 Nanobiotix 1,933.82 Bn 1,933.76 Bn - -
3 Akari Therapeutics 1,022.34 Bn 1,022.34 Bn - -14.46 Mn
4 BeOne Medicines 472.93 Bn 468.14 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 122.22 Bn 114.98 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 69.96 Bn 61.21 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 62.66 Bn 62.66 Bn - -26.94 Mn
8 Argenx Se 56.07 Bn 50.89 Bn 1.41 Bn 362.00 Mn
9 Alnylam Pharmaceuticals 37.60 Bn 34.59 Bn 959.66 Mn 205.99 Mn
10 Scholar Rock Holding 6.32 Bn 6.32 Bn - -101.45 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -101.45 Mn
Dec 31, 2025 -89.48 Mn
Sep 30, 2025 -260.46 Mn
Jun 30, 2025 -263.83 Mn
Mar 31, 2025 -74.91 Mn
Dec 31, 2024 -67.66 Mn
Sep 30, 2024 -65.66 Mn
Jun 30, 2024 -60.31 Mn
Mar 31, 2024 -56.83 Mn
Dec 31, 2023 -49.69 Mn
Sep 30, 2023 -46.00 Mn
Jun 30, 2023 -42.09 Mn
Mar 31, 2023 -44.43 Mn
Dec 31, 2022 -41.77 Mn
Sep 30, 2022 -46.45 Mn
Jun 30, 2022 -43.90 Mn
Mar 31, 2022 -9.20 Mn
Dec 31, 2021 -35.95 Mn
Sep 30, 2021 -87.69 Mn
Jun 30, 2021 -77.06 Mn